Drugs Made In America II: Karpus reports 5.18% stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Drugs Made In America Acquisition II Corp. (DMII) is the issuer whose common shares Karpus Management, Inc. reported beneficially owning: 3,300,023 shares, or 5.18%, as of September 30, 2026. The shares are owned directly by accounts managed by Karpus. Karpus stated it exercises voting and investment power independently of its parent, City of London Investment Group plc, under informational barriers, and that beneficial ownership attribution between them is not required.
Key Figures
Key Terms
beneficially owned regulatory
sole voting power regulatory
sole dispositive power regulatory
registered investment adviser regulatory
informational barriers regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Was Karpus Management’s DMII stake attributed to its parent, City of London Investment Group?
AI-generated analysis. How Rhea-AI works. Not financial advice.